Cowen & Co Upgrades Merck (MRK) to Outperform
More News related to MRK
- Notable Midday ETF Movers 11/20: XLV, EWJ Higher; XHB, XLE, SMH Lower
- Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
- Merck (MRK) Announces Results of COZAAR Study; Increased Dose Reduced Death or Hospitalization from Heart Failure
Cowen & Co upgrades Merck (NYSE: MRK) from Neutral to Outperform.
To see more analyst ratings on MRK Click Here.
Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health.
Related Categories
UpgradesStocks Mentioned
+1.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
